Results 51 to 60 of about 1,716,661 (233)

A TCR-based Chimeric Antigen Receptor

open access: yesScientific Reports, 2017
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection.
Even Walseng   +8 more
doaj   +1 more source

The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules [PDF]

open access: yes, 1992
Recent studies have demonstrated that the CD3-ζ subunit of the T cell antigen receptor (TCR) complex is involved in signal transduction. However, the function of the remaining invariant subunits, CD3-γ, -δ, and , is still poorly understood.
Wegener, Anne-Marie K.   +19 more
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Natural killer cell immunotherapy in glioblastoma

open access: yesDiscover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh   +5 more
doaj   +1 more source

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia [PDF]

open access: yes, 2015
Current therapies for acute myeloid leukemia are associated with high failure and relapse rates. Adoptive immunotherapies, which have shown promise in the treatment of hematologic malignancies, have the potential to target acute myeloid leukemia through ...
Joshua F. Heiber   +4 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

open access: yesBMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita   +7 more
doaj   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

open access: yesCells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt   +2 more
doaj   +1 more source

The ubiquitin system in normal and infected germinal center B cells

open access: yesFEBS Letters, EarlyView.
The ubiquitin system plays a central role in germinal center (GC) B cells, influencing differentiation to long‐lived memory B cells. Oncogenic gammaherpesviruses gain access to memory B cells by establishing latency in GC B cells. Mapping ubiquitin mechanisms in normal and infected GC B cells will define specific molecular circuits in B cells germane ...
Destiny Davis   +2 more
wiley   +1 more source

A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer. [PDF]

open access: yesAdv Sci (Weinh)
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Wang L   +8 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy